Ulcerative Colitis: Update on Medical Management

Overview

Journal Curr Gastroenterol Rep

Specialty Gastroenterology

Date 2015 Sep 21

PMID 26386686

Citations 18

Authors

Heba N Iskandar

Tanvi Dhere

Francis A Farraye

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease whose pathogenesis is multifactorial and includes influences from genes, the environment, and the gut microbiome. Recent advances in diagnosis and treatment have led to significant improvement in managing the disease. Disease monitoring with the use of therapeutic drug monitoring, stool markers, and assessment of mucosal healing have garnered much attention. The recent approval of vedolizumab for treatment of moderate to severe UC has been a welcome addition. Newer biologics, including those targeting the Janus tyrosine kinase (JAK) pathway, are on the horizon to add to the current armamentarium of anti-TNF alpha and anti-integrin therapies. The recent publication of the SCENIC consensus statement on surveillance and management of dysplasia in UC patients supports the use of chromoendoscopy over random biopsies in detecting dysplasia. This review highlights these recent advances along with others that have been made with ulcerative colitis.

Citing Articles

Expression of MAF bZIP transcription factor B protects against ulcerative colitis through the inhibition of the NF-κB pathway.

Li J, Li Q, Ma W, Zhang Y, Li X Immun Inflamm Dis. 2024; 12(8):e1372.

PMID: 39172054 PMC: 11340633. DOI: 10.1002/iid3.1372.

Study on the function of Huazhuo Jiedu Decoction in promoting the homing of bone marrow mesenchymal stem cells and contributing to the treatment of ulcerative colitis.

Ma Y, Li Y, Zhang S, Liu Z, Du L, Zhang X Heliyon. 2023; 9(8):e18802.

PMID: 37576246 PMC: 10415889. DOI: 10.1016/j.heliyon.2023.e18802.

Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.

Shi M, Liu L, Yang F World J Stem Cells. 2022; 14(9):684-699.

PMID: 36188115 PMC: 9516464. DOI: 10.4252/wjsc.v14.i9.684.

Anti-inflammatory effects of anemonin on acute ulcerative colitis via targeted regulation of protein kinase C-θ.

Jiang L, Chi C, Yuan F, Lu M, Hu D, Wang L Chin Med. 2022; 17(1):39.

PMID: 35346284 PMC: 8962473. DOI: 10.1186/s13020-022-00599-3.

Cherry Polyphenol Extract Ameliorated Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice by Suppressing Wnt/β-Catenin Signaling Pathway.

Li F, Yan H, Jiang L, Zhao J, Lei X, Ming J Foods. 2022; 11(1).

PMID: 35010176 PMC: 8750665. DOI: 10.3390/foods11010049.

References

Travis S, Danese S, Kupcinskas L, Alexeeva O, DHaens G, Gibson P . Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2013; 63(3):433-41. PMC: 3933176. DOI: 10.1136/gutjnl-2012-304258. View

Shen J, Zuo Z, Mao A . Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2013; 20(1):21-35. DOI: 10.1097/01.MIB.0000437495.30052.be. View

Kiesslich R, Neurath M . Surveillance colonoscopy in ulcerative colitis: magnifying chromoendoscopy in the spotlight. Gut. 2004; 53(2):165-7. PMC: 1774930. DOI: 10.1136/gut.2003.026351. View

Panaccione R, Ghosh S, Middleton S, Marquez J, Scott B, Flint L . Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014; 146(2):392-400.e3. DOI: 10.1053/j.gastro.2013.10.052. View

Ananthakrishnan A . Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci. 2014; 60(2):290-8. PMC: 4304948. DOI: 10.1007/s10620-014-3350-9. View

Vermeire S . Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease. Aliment Pharmacol Ther. 2006; 24 Suppl 3:2-10. DOI: 10.1111/j.1365-2036.2006.03052.x. View

Kornbluth A, Sachar D . Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105(3):501-23. DOI: 10.1038/ajg.2009.727. View

Hirschfield G, Karlsen T, Lindor K, Adams D . Primary sclerosing cholangitis. Lancet. 2013; 382(9904):1587-99. DOI: 10.1016/S0140-6736(13)60096-3. View

Khor B, Gardet A, Xavier R . Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474(7351):307-17. PMC: 3204665. DOI: 10.1038/nature10209. View

10.

Sinclair J, Wasan S, Farraye F . Health maintenance in the inflammatory bowel disease patient. Gastroenterol Clin North Am. 2012; 41(2):325-37. DOI: 10.1016/j.gtc.2012.01.006. View

11.

van den Broek F, Stokkers P, Reitsma J, Boltjes R, Ponsioen C, Fockens P . Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol. 2011; 109(5):715-22. DOI: 10.1038/ajg.2011.93. View

12.

Ott C, Scholmerich J . Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013; 10(10):585-95. DOI: 10.1038/nrgastro.2013.117. View

13.

Marion J, Waye J, Present D, Israel Y, Bodian C, Harpaz N . Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008; 103(9):2342-9. DOI: 10.1111/j.1572-0241.2008.01934.x. View

14.

Barreiro-de Acosta M, Magro F, Carpio D, Lago P, Echarri A, Cotter J . Ulcerative colitis in northern Portugal and Galicia in Spain. Inflamm Bowel Dis. 2009; 16(7):1227-38. DOI: 10.1002/ibd.21170. View

15.

Panes J, Su C, Bushmakin A, Cappelleri J, Mamolo C, Healey P . Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol. 2015; 15:14. PMC: 4323227. DOI: 10.1186/s12876-015-0239-9. View

16.

Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein C, Brant S . Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 Suppl A:5A-36A. DOI: 10.1155/2005/269076. View

17.

Danese S, Panes J . Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 2014; 147(5):981-9. DOI: 10.1053/j.gastro.2014.08.044. View

18.

Konijeti G, Shrime M, Ananthakrishnan A, Chan A . Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc. 2013; 79(3):455-65. PMC: 4116277. DOI: 10.1016/j.gie.2013.10.026. View

19.

Jess T, Simonsen J, Jorgensen K, Pedersen B, Nielsen N, Frisch M . Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012; 143(2):375-81.e1. DOI: 10.1053/j.gastro.2012.04.016. View

20.

Manolakis C, Cash B . Health maintenance and inflammatory bowel disease. Curr Gastroenterol Rep. 2014; 16(10):402. DOI: 10.1007/s11894-014-0402-4. View